0000000000610489

AUTHOR

Joachim Gerss

showing 4 related works from this author

The randomized shortened dental arch study: tooth loss.

2010

The evidence concerning the management of shortened dental arch (SDA) cases is sparse. This multi-center study was aimed at generating data on outcomes and survival rates for two common treatments, removable dental prostheses (RDP) for molar replacement or no replacement (SDA). The hypothesis was that the treatments lead to different incidences of tooth loss. We included 215 patients with complete molar loss in one jaw. Molars were either replaced by RDP or not replaced, according to the SDA concept. First tooth loss after treatment was the primary outcome measure. This event occurred in 13 patients in the RDP group and nine patients in the SDA group. The respective Kaplan-Meier survival r…

MolarMaleRandomizationmedicine.medical_treatmentDentistryKaplan-Meier Estimatelaw.inventionTooth LossDental Archstomatognathic systemRandomized controlled triallawOral and maxillofacial pathologyTooth lossMedicineHumansGeneral DentistryOrthodonticsbusiness.industryDental prosthesisMiddle Agedmedicine.diseaseMolarDental archmedicine.anatomical_structureDenture Partial RemovableFemalemedicine.symptombusinessProsthodonticsJournal of dental research
researchProduct

The randomized shortened dental arch study (RaSDA): design and protocol

2010

Abstract Background Various treatment options for the prosthetic treatment of jaws where all molars are lost are under discussion. Besides the placement of implants, two main treatment types can be distinguished: replacement of the missing molars with removable dental prostheses and non-replacement of the molars, i.e. preservation of the shortened dental arch. Evidence is lacking regarding the long-term outcome and the clinical performance of these approaches. High treatment costs and the long time required for the treatment impede respective clinical trials. Methods/design This 14-center randomized controlled investigator-initiated trial is ongoing. Last patient out will be in 2010. Patien…

AdultResearch designTime FactorsMedicine (miscellaneous)DentistryPilot ProjectsProsthesis Designlaw.inventionTooth LossDental ArchPatient satisfactionstomatognathic systemRandomized controlled trialQuality of lifelawGermanyStudy protocolTooth lossPremolarHumansMedicinePharmacology (medical)Orthodonticslcsh:R5-920business.industryJaw Edentulous PartiallyClinical trialDental ImplantationDental archTreatment Outcomemedicine.anatomical_structurePatient SatisfactionResearch DesignQuality of LifeDenture Partial FixedDenture Partial Removablemedicine.symptomlcsh:Medicine (General)businessTrials
researchProduct

Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK)

2020

Abstract Introduction Extracranial rhabdoid tumours are rare, highly aggressive malignancies primarily affecting young children. The EU-RHAB registry was initiated in 2009 to prospectively collect data of rhabdoid tumour patients treated according to the EU-RHAB therapeutic framework. Methods We evaluated 100 patients recruited within EU-RHAB (2009–2018). Tumours and matching blood samples were examined for SMARCB1 mutations by sequencing and cytogenetics. Results A total of 70 patients presented with extracranial, extrarenal tumours (eMRT) and 30 with renal rhabdoid tumours (RTK). Nine patients demonstrated synchronous tumours. Distant metastases at diagnosis (M+) were present in 35% (35/1…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentMedizin03 medical and health sciences0302 clinical medicineRisk groupsGermline mutationRisk FactorsInternal medicinemedicineHumansGenetic riskSMARCB1ChildLymph nodeRhabdoid TumorUnivariate analysisbusiness.industryCytogeneticsInfant NewbornInfantRadiation therapy030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisChild PreschoolFemalebusinessEuropean Journal of Cancer
researchProduct

Prognostic Factors of Papillary Renal Cell Carcinoma: Results From a Multi-Institutional Series After Pathological Review

2009

We examined papillary renal cell carcinoma prognostic variables and validated the 2002 UICC TNM staging system in a multicenter analysis.From 10 urological institutions in Germany followup data were collected on a total of 675 patients with papillary renal cell carcinoma. Central pathological review was done to validate external histopathological diagnoses. The Kaplan-Meier method was used to derive cumulative cancer specific and overall survival, and the log rank test was used to compare the curves of 2 or more groups. For multivariate analysis of prognostic factors Cox regression analysis was done. All proportional hazard assumptions were systemically verified using the Grambsch-Therneau …

MaleOncologymedicine.medical_specialtyPathologyPrognostic variableUrologyTNM staging systemRenal cell carcinomaInternal medicinemedicineCarcinomaHumansCarcinoma Renal CellNeoplasm StagingRetrospective StudiesPapillary renal cell carcinomasProportional hazards modelbusiness.industryCancerMiddle AgedPrognosismedicine.diseaseKidney NeoplasmsSurvival RateLog-rank testFemalebusinessJournal of Urology
researchProduct